Short: The Real Reason You're Not Losing Weight On A GLP-1

Your appetite disappears on a GLP-1, so you stop eating, and the scale drops fast, and it feels like the drug is working exactly the way it should. But most of that early drop is not fat. It is water and stored glycogen leaving your body, because each gram of glycogen holds three to four grams of water, and when you suddenly eat far less, your body burns through those glycogen stores quickly and releases all that bound water with them. The scale can move five, eight, ten pounds in a matter of days from that mechanism alone.

Then the scale slows down or stops completely, and people assume the drug stopped working.

The drug did not stop working. Something else happened inside the window the drug created.

Here is the full chain so you can see where the problem actually lives. GLP-1 receptor agonists work by mimicking something called GLP-1, which is a hormone your gut releases after eating that signals your brain to slow digestion, reduce hunger, and stop eating sooner. When you take a medication that activates those receptors continuously, your appetite does not just decrease, it can nearly disappear. So your total food intake drops dramatically, and your protein intake drops with it, because protein does not come from nowhere, it comes from the food you are eating less of.

When protein drops too low, your body enters what you could call triage mode.

Your body has a hierarchy of priorities, and keeping you alive today ranks above keeping you lean over the next year. Muscle tissue is metabolically expensive, meaning it burns calories just to maintain itself, and when your body is running low on protein and sees no strong signal that those muscles are being used, it treats lean mass as a resource rather than an asset. It breaks muscle down to harvest the amino acids inside, which it then uses for the processes it cannot shut off, like organ function, immune response, and basic cellular repair.

Less muscle means a lower resting metabolic rate, because muscle tissue burns roughly six calories per pound per day just to exist, and when that mass shrinks, the number of calories your body burns at rest shrinks with it. So the calorie deficit that was producing results early on gets smaller and smaller even if you are eating the same amount, and eventually the deficit disappears entirely. That is the plateau. Not a mystery, not a broken drug, just a shrinking engine.

The way to fix this is to protect the engine while the drug does its job on fat.

Protein is the first lever. Your goal body weight in grams per day, every day, regardless of hunger. If your goal weight is 170 pounds, you are aiming for 170 grams of protein daily. This is not comfortable on a GLP-1 because your appetite is suppressed, which is exactly why it has to be treated like a prescription rather than a preference. You hit the number even when you do not feel like eating, because the alternative is your body deciding it does not need the muscle that number is protecting.

The second lever is resistance training. Two to three sessions per week is enough to send the signal your body needs, which is that the muscle is being challenged and therefore should not be broken down. Without that signal, high protein alone is not sufficient to fully preserve lean mass in a significant caloric deficit. The training tells your body the muscle is earning its place.

A case series published in 2025 showed what happens when patients on semaglutide or tirzepatide do both of these things consistently. Patients who trained three to five times per week and prioritized protein lost an average of 33 percent of their body weight, but only 6.9 percent of that came from muscle mass. One patient lost 26.8 percent of their body weight and actually gained 2.5 percent lean mass during the process. Same class of drug, same suppressed appetite, completely different body composition outcomes, and the variable was protein and training.

The comparison matters because without those interventions, research on GLP-1 induced weight loss shows lean mass losses that can represent 25 to 40 percent of total weight lost, which is a significant portion of the weight coming off as muscle rather than fat. The drug does not discriminate. It just reduces intake. What your body pulls from to make up the deficit depends on the signals you give it.

There is something worth understanding about timing here. The window the drug creates, where your hunger is low and your deficit is easy to maintain, is finite. Either you stop the medication eventually, or you develop some tolerance, or the weight loss phase ends. If you used that window to preserve or build lean mass, your resting metabolism is intact and your results hold. If you used that window only to eat less, the weight often comes back because the engine that would have burned those calories got smaller while you were not paying attention.

The drug does not change what makes weight loss work. It just makes one part of it easier to sustain. The part it does not help with, protecting muscle, still requires the same inputs it always did.

---

References

1. Tinsley GM, Nadolsky S. Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medical Case Reports. 2025. Finding: Patients on semaglutide/tirzepatide who trained 3-5x/week and prioritized protein lost 33% body weight with only 6.9% muscle loss; one gained 2.5% muscle while losing 26.8% body weight. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness